| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 2014 | Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. | Hsu, YH; Yao, J; Chan, LC; Wu, TJ; Hsu, JL; Fang, YF; Wei, Y; Wu, Y; Huang, WC; Liu, CL; Chang, YC; Wang, MY; Li, CW ; Shen, J; Chen, MK; Sahin, AA; Sood, A; Mills, GB; Yu, D; Hortobagyi, GN; Hung, MC | Cancer research 74(17), 4822-4835 | | | |
| 2018 | Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. | Shao, B; Li, CW; Lim, SO; Sun, L; Lai, YJ; Hou, J; Liu, C; Chang, CW; Qiu, Y; Hsu, JM; Chan, LC; Zha, Z; Li, H; Hung, MC | American journal of cancer research 8(9), 1837-1846 | | | |
| 2016 | Deubiquitination and Stabilization of PD-L1 by CSN5. | Lim, SO; Li, CW ; Xia, W; Cha, JH; Chan, LC; Wu, Y; Chang, SS; Lin, WC; Hsu, JM; Hsu, YH; Kim, T; Chang, WC; Hsu, JL; Yamaguchi, H; Ding, Q; Wang, Y; Yang, Y; Chen, CH; Sahin, AA; Yu, D; Hortobagyi, GN; Hung, MC | Cancer cell 30(6), 925-939 | | | |
| 2018 | Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. | Li, CW; Lim, SO; Chung, EM; Kim, YS; Park, AH; Yao, J; Cha, JH; Xia, W; Chan, LC; Kim, T; Chang, SS; Lee, HH; Chou, CK; Liu, YL; Yeh, HC; Perillo, EP; Dunn, AK; Kuo, CW; Khoo, KH ; Hsu, JL; Wu, Y; Hsu, JM; Yamaguchi, H; Huang, TH; Sahin, AA; Hortobagyi, GN; Yoo, SS; Hung, MC | Cancer cell 33(2), 187-201.e10 | | | |
| 2018 | Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. | Yang, Y; Li, CW; Chan, LC; Wei, Y; Hsu, JM; Xia, W; Cha, JH; Hou, J; Hsu, JL; Sun, L; Hung, MC | Cell research 28(8), 862-864 | | | |
| 2016 | Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. | Li, CW ; Lim, SO; Xia, W; Lee, HH; Chan, LC; Kuo, CW; Khoo, KH ; Chang, SS; Cha, JH; Kim, T; Hsu, JL; Wu, Y; Hsu, JM; Yamaguchi, H; Ding, Q; Wang, Y; Yao, J; Lee, CC; Wu, HJ; Sahin, AA; Allison, JP; Yu, D; Hortobagyi, GN; Hung, MC | Nature communications 7, 12632 | | | |
| 2016 | GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. | Ko, HW; Lee, HH; Huo, L; Xia, W; Yang, CC; Hsu, JL; Li, LY; Lai, CC; Chan, LC; Cheng, CC; Labaff, AM; Liao, HW; Lim, SO; Li, CW ; Wei, Y; Nie, L; Yamaguchi, H; Hung, MC | Oncotarget 7(35), 57131-57144 | | | |
| 2018 | Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. | Sun, LL; Yang, RY; Li, CW; Chen, MK; Shao, B; Hsu, JM; Chan, LC; Yang, Y; Hsu, JL; Lai, YJ; Hung, MC | American journal of cancer research 8(7), 1307-1316 | | | |
| 2018 | Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. | Cha, JH; Yang, WH; Xia, W; Wei, Y; Chan, LC; Lim, SO; Li, CW; Kim, T; Chang, SS; Lee, HH; Hsu, JL; Wang, HL; Kuo, CW; Chang, WC; Hadad, S; Purdie, CA; McCoy, AM; Cai, S; Tu, Y; Litton, JK; Mittendorf, EA; Moulder, SL; Symmans, WF; Thompson, AM; Piwnica-Worms, H; Chen, CH; Khoo, KH ; Hung, MC | Molecular cell 71(4), 606-620.e7 | | | |
| 2019 | Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer. | Han, Y; Li, CW ; Hsu, JM; Hsu, JL; Chan, LC; Tan, X; He, GJ | American journal of cancer research 9(4), 800-815 | | | |
| 2019 | Palmitoylation stabilizes PD-L1 to promote breast tumor growth. | Yang, Y; Hsu, JM; Sun, L; Chan, LC; Li, CW ; Hsu, JL; Wei, Y; Xia, W; Hou, J; Qiu, Y; Hung, MC | Cell research 29(1), 83-86 | | | |
| 2015 | Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. | Rahal, OM; Nie, L; Chan, LC; Li, CW ; Hsu, YH; Hsu, J; Yu, D; Hung, MC | American journal of cancer research 5(12), 3624-3634 | | | |
| 2018 | STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. | Hsu, JM; Xia, W; Hsu, YH; Chan, LC; Yu, WH; Cha, JH; Chen, CT; Liao, HW; Kuo, CW; Khoo, KH ; Hsu, JL; Li, CW; Lim, SO; Chang, SS; Chen, YC; Ren, GX; Hung, MC | Nature communications 9(1), 1908 | | | |
| 2019 | Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. | Han, Y; Chen, MK; Wang, HL; Hsu, JL; Li, CW ; Chu, YY; Liu, CX; Nie, L; Chan, LC; Yam, C; Wang, SC; He, GJ; Hortobagyi, GN; Tan, XD; Hung, MC | American journal of cancer research 9(3), 608-618 | | | |
